Drug intelligence / Profile preview

INT-2150

Development stage: Phase 1
Lead developer: Kukje Pharm
Modality: Small Molecules
Administration: Oral

Overview

INT-2150 is a small molecule drug under development by Kukje Pharma for the treatment of gastritis. Its precise mechanism of action has not been disclosed or remains unknown. The drug has reached Phase 1 clinical trials, where it was evaluated for safety and pharmacokinetic characteristics after oral administration in healthy adult male subjects. There are no known adverse events reported, and it does not have any FDA designation or approval in any country as of the latest available data.

Beyond the preview

Go deeper on INT-2150.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on INT-2150.

Explore the full profile